Clinical trials: Recurrent ALK Positive Large B-Cell Lymphoma
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after…
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT06834373
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
This phase II trial studies how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back (recurrent) or do not respond to treatment (refractory).
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Trial name
- NCT03038672
- Testing
- Nivolumab, Varlilumab
- Where
- 33 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04476459
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Huiqiang Huang
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a…
- Conditions
- Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT05507541
- Testing
- Biospecimen Collection, Computed Tomography, Ontorpacept
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic